^
Association details:
| Biomarker: | CSF2 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | TriMix-DC (ex-vivo autologous dendritic cells vaccine) (CD70 inhibitor, CD40 agonist, TLR4 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
Published date:
06/26/2020
Excerpt:
Forty-one patients were randomly assigned to treatment with TriMixDC-MEL (n = 21) and standard follow-up (n = 20)...The mRNA expression profiling revealed four genes (STAT2, TPSAB1, CD9 and CSF2) as potential predictive biomarkers….TriMixDC-MEL id/iv as adjuvant therapy is tolerable and may improve the 1-year disease-free survival rate.
DOI:
10.1007/s00262-020-02618-4
